Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Type 2 diabetes: Both Trulicity and Ozempic are approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes in tandem with exercise and diet. Cardiovascular risk: Both ...

Some Medicare plans may cover Trulicity for people with type 2 diabetes, but there will be some out-of-pocket costs. Learn more here.

In diabetes, injectable GLP-1 analog Ozempic (patent 2032) looks best-in-class over Lilly's Trulicity, and oral Rybelsus (patent 2032) expands reach into the oral diabetes treatment market.

Trulicity (dulaglutide) — The FDA approved the active ingredient in 2014, and Eli Lilly’s Type 2 diabetes injectable medicine secured U.S. approval in 2020.

Our estimates for Trulicity, Taltz, Verzenio, Jardiance, Olumiant, and Emgality are $1.17 billion, $659 million, $1.23 billion, $775.8 million, $240.3 million and $277.8 million, respectively.

Some Medicare plans may cover Trulicity for people with type 2 diabetes, but there will be some out-of-pocket costs. Learn more here.

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4% in 2022. As a result, annual spending jumped from $1.6 billion to $5. ...

Switching between Trulicity and Mounjaro may be an option for people with type 2 diabetes, depending on their treatment needs and goals. Cost, availability, and tolerability should be considered when ...